Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: from molecular design to application
Photodynamic therapy (PDT), a therapeutic mode involving light triggering, has been
recognized as an attractive oncotherapy treatment. However, nonnegligible challenges …
recognized as an attractive oncotherapy treatment. However, nonnegligible challenges …
Ruthenium complexes as anticancer agents: A brief history and perspectives
SY Lee, CY Kim, TG Nam - Drug design, development and therapy, 2020 - Taylor & Francis
Platinum (Pt)-based anticancer drugs such as cisplatin have been used to treat various
cancers. However, they have some limitations including poor selectivity and toxicity towards …
cancers. However, they have some limitations including poor selectivity and toxicity towards …
Hypoxia-targeted drug delivery
Hypoxia is a state of low oxygen tension found in numerous solid tumours. It is typically
associated with abnormal vasculature, which results in a reduced supply of oxygen and …
associated with abnormal vasculature, which results in a reduced supply of oxygen and …
NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: A case story in medicinal inorganic chemistry
NAMI-A ((ImH)[trans-RuCl4 (dmso-S)(Im)], Im= imidazole) and KP1019/1339
(KP1019=(IndH)[trans-RuCl4 (Ind) 2], Ind= indazole; KP1339= Na [trans-RuCl4 (Ind) 2]) are …
(KP1019=(IndH)[trans-RuCl4 (Ind) 2], Ind= indazole; KP1339= Na [trans-RuCl4 (Ind) 2]) are …
Thirty years of the drug candidate NAMI‐A and the myths in the field of ruthenium anticancer compounds: a personal perspective
E Alessio - European Journal of Inorganic Chemistry, 2017 - Wiley Online Library
As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
S Leijen, SA Burgers, P Baas, D Pluim, M Tibben… - Investigational new …, 2015 - Springer
Summary Background This phase I/II study determined the maximal tolerable dose, dose
limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of …
limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of …
Redox activation of metal-based prodrugs as a strategy for drug delivery
N Graf, SJ Lippard - Advanced drug delivery reviews, 2012 - Elsevier
This review provides an overview of metal-based anticancer drugs and drug candidates. In
particular, we focus on metal complexes that can be activated in the reducing environment of …
particular, we focus on metal complexes that can be activated in the reducing environment of …
Anticancer activity of metal complexes: involvement of redox processes
U Jungwirth, CR Kowol, BK Keppler, CG Hartinger… - 2011 - liebertpub.com
Cells require tight regulation of the intracellular redox balance and consequently of reactive
oxygen species for proper redox signaling and maintenance of metal (eg, of iron and …
oxygen species for proper redox signaling and maintenance of metal (eg, of iron and …
Arene ruthenium complexes as anticancer agents
G Süss-Fink - Dalton Transactions, 2010 - pubs.rsc.org
Neutral or cationic arene ruthenium complexes providing both hydrophilic as well as
hydrophobic properties due to the robustness of the ruthenium–arene unit hold a high …
hydrophobic properties due to the robustness of the ruthenium–arene unit hold a high …
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and
two of them have entered clinical trials. Compared to platinum drugs, the complexes based …
two of them have entered clinical trials. Compared to platinum drugs, the complexes based …